Method for alleviating pain using sphingosine-1-phosphate and related compounds, and assays for identifying such compounds
View Patent ↗Methods for alleviating pain comprising administering to a subject sphingosine-1-phosphate, functional fragments and derivatives thereof, and other compounds, and assays for identifying such compounds.
1. A method of screening a compound that has S1P activity, the method comprising the steps of
a. providing a first sample comprising a candidate compound and PAM (protein associated with Myc) having activity to lower intracellular cyclic AMP levels and to inhibit adenylyl cyclase I, V, or VI activity, and having the amino acid sequence of SEQ ID NO: 2 or a functional fragment thereof selected from the group consisting of: (i) amino acids 400 to 1400 of SEQ ID NO: 2; (ii) amino acids 446 to 1062 of SEQ ID NO: 2; (iii) amino acids 499 to 1065 of SEQ ID NO: 2; (iv) amino acids 1028 to 1231 of SEQ ID NO: 2; (v) amino acids 1000 to 1300 of SEQ ID NO: 2; (vi) amino acids 1000 to 1100 of SEQ ID NO: 2; and (vii) amino acids 1028 to 1065 of SEQ ID NO: 2, wherein the first sample does not comprise S1P (sphingosine-1-phosphate) having the structure set forth in FIG. 15 ;
b. providing a second sample comprising PAM having activity to lower intracellular cyclic AMP levels and to inhibit adenylyl cyclase I, V, or VI activity, and having the amino acid sequence of SEQ ID NO: 2 or a functional fragment thereof selected from the group consisting of: (i) amino acids 400 to 1400 of SEQ ID NO: 2; (ii) amino acids 446 to 1062 of SEQ ID NO: 2; (iii) amino acids 499 to 1065 of SEQ ID NO: 2; (iv) amino acids 1028 to 1231 of SEQ ID NO: 2; (v) amino acids 1000 to 1300 of SEQ ID NO: 2; (vi) amino acids 1000 to 1100 of SEQ ID NO: 2; and (vii) amino acids 1028 to 1065 of SEQ ID NO: 2 and S1P having the structure set forth in FIG. 15 ;
c. contacting the first sample with the compound; and
d. measuring PAM activity in the first and second samples,
wherein the measurement of PAM activity in the first sample is equal to or greater than the measurement of PAM activity in the second sample is indicative that the compound has S1P activity of the S1P having the structure set forth in FIG. 15 .
2. The method of claim 1 , wherein the functional fragment of PAM is a polypeptide encoded by a nucleic acid sequence selected from the group consisting of nucleotides 1482 to 3332 of SEQ ID NO. 1, nucleotides 1641 to 3341 of SEQ ID NO. 1, and nucleotides 3228 to 3839 of SEQ ID NO. 1.